Tofacitinib Combined With Chidamide in R/R ENKTCL
This study is to explore the efficacy and safety of tofacitinib combined with chidamide in patients with relapsed and refractory extranodal NK/T cell lymphoma.
Extranodal NK/T-cell Lymphoma
DRUG: tofacitinib|DRUG: chidamide
2-year progression free survival, 2 years after recruitment
complete remission, 4 months after treatment|adverse events (AEs), 2 years after recruitment|2-year overall survival, 2 years after recruitment
This study is to explore the efficacy and safety of tofacitinib combined with chidamide in patients with relapsed and refractory extranodal NK/T cell lymphoma.